Guanhao Zheng
Overview
Explore the profile of Guanhao Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gao S, Zheng G, He Z, Chen L, Yan D, Lai Z, et al.
Ther Innov Regul Sci
. 2024 Oct;
59(1):135-141.
PMID: 39453599
Background And Objective: Denosumab is widely used for osteoporosis and cancer treatment. However, hypocalcemia induced by denosumab is a frequent adverse event. The objective of this study is to comprehensively...
2.
Zheng G, Cai J, Deng H, Yang H, Xiong W, Chen E, et al.
Antimicrob Resist Infect Control
. 2024 Apr;
13(1):46.
PMID: 38659068
Background: Colonization of carbapenem-resistant Enterobacterale (CRE) is considered as one of vital preconditions for infection, with corresponding high morbidity and mortality. It is important to construct a reliable prediction model...
3.
Cai J, Yang M, Deng H, Bai H, Zheng G, He J
Ther Adv Infect Dis
. 2024 Feb;
11:20499361241231147.
PMID: 38410828
Background: Considering the therapeutic difficulties and mortality associated with bloodstream infection (BSI), it is essential to investigate other potential factors affecting mortality in critically ill patients with BSI and examine...
4.
Zheng G, Cai J, Zhang L, Chen D, Wang L, Qiu Y, et al.
Infect Dis Ther
. 2022 Aug;
11(5):1917-1934.
PMID: 35976531
Introduction: Considering the importance of ceftazidime/avibactam (CAZ/AVI) and polymyxin B (PMB) in treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infection, it is essential to evaluate the efficacy and safety of these agents...
5.
Zheng G, Cai J, Zhou S, Du N, Bai H, He J, et al.
Per Med
. 2022 Jun;
19(4):307-314.
PMID: 35762314
To observe the difference in the risk of polymyxin B (PMB)-induced acute kidney injury (AKI) with or without dose adjustment based on the patients renal function. This retrospective cohort analysis...
6.
Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et al.
Infect Dis Ther
. 2022 Feb;
11(2):935-936.
PMID: 35226348
No abstract available.
7.
Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et al.
Infect Dis Ther
. 2021 Jul;
10(3):1699-1713.
PMID: 34241831
Background: No clinical study has investigated the use of ceftazidime-avibactam combination schemes with an in vitro non-susceptible antimicrobial that could be superior to ceftazidime-avibactam monotherapy against carbapenem-resistant Klebsiella pneumoniae. Methods:...
8.
He J, Zheng G, Qian X, Sheng H, Chen B, Zhao B, et al.
Curr Med Res Opin
. 2021 Feb;
37(4):555-565.
PMID: 33560893
Introduction: High-dose vitamin C is an essential adjunctive drug for sepsis treatment. This study aimed to determine if high-dose vitamin C could lead to erroneous point-of-care glucose testing results. Methods...
9.
Lin C, Luo N, Xu Q, Zhang J, Cai M, Zheng G, et al.
BMC Infect Dis
. 2019 Oct;
19(1):869.
PMID: 31640582
Background: Pandoraea species is a newly described genus, which is multidrug resistant and difficult to identify. Clinical isolates are mostly cultured from cystic fibrosis (CF) patients. CF is a rare...
10.
Zheng G, Cao L, Che Z, Mao E, Chen E, He J
BMC Pharmacol Toxicol
. 2018 Jul;
19(1):41.
PMID: 29973293
Background: Polymyxin B (PMB), which is regarded as the ultimate antibacterial treatment against some intractable gram-negative bacteria with its outstanding anti-bacterial activities, inflicts several adverse effects on patients. However, skin...